...
首页> 外文期刊>Tumour biology : >MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma
【24h】

MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma

机译:MiRNA表达特征可潜在预测卵巢浆液性癌的预后

获取原文
获取原文并翻译 | 示例
           

摘要

One of the best prognostic predictors for patients with epithelial ovarian cancer is the Federation of Obstetrics and Gynecology (FIGO) stage at diagnosis. Advanced-stage ovarian serous carcinoma (OSC) generally have poor prognosis. The goal of this study is to develop and validate a miRNA expression profile that can differentiate the OSC at early and advanced stages and study its correlation with the prognosis of OSC. To identify a unique microRNA (miRNA) pattern associated with the progression of OSC at early and advanced stages, a miRNA microarray was performed using Chinese tumor bank specimens of patients with OSC stage I or III in a retrospective analysis. The expression of four dysregulated miRNAs was validated using quantitative real-time polymerase chain reaction (qRT-PCR) in an external cohort of 51 cases of OSC samples at stages I and III. Kaplan-Meier analysis was performed to analyze the correlation between the expression of some miRNAs and prognosis. Of the 768 miRNAs analyzed in the microarray, 26 miRNAs were significantly either up- or downregulated, with at least a 2-fold difference, in OSC stage I compared with stage III. The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results. Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05). Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome.
机译:上皮性卵巢癌患者最好的预后指标之一是诊断时的妇产科联合会(FIGO)阶段。晚期卵巢浆液性癌(OSC)通常预后不良。这项研究的目的是开发和验证可以在早期和晚期区分OSC的miRNA表达谱,并研究其与OSC预后的相关性。为了确定与OSC早期和晚期阶段进展相关的独特microRNA(miRNA)模式,采用回顾性分析方法,使用OSC I或III期患者的中国肿瘤库标本进行miRNA微阵列分析。使用定量实时聚合酶链反应(qRT-PCR)在51个病例的I和III期OSC样本的外部队列中验证了四个失调的miRNA的表达。进行Kaplan-Meier分析以分析一些miRNA的表达与预后之间的相关性。在微阵列中分析的768个miRNA中,与III期相比,OSC I期中有26种miRNA显着上调或下调,差异至少2倍。 qRT-PCR结果显示,与I期相比,III期OSC中miR-510,miR-509-5p和miR-508-3p显着下调,而miR-483-5p被上调。结果。 Kaplan-Meier分析显示低miR-510表达,低miR-509-5p表达和晚期FIGO分期,化疗耐药与较差的总生存率显着相关(P <0.05)。我们的结果表明,miRNA可能在OSC的进程中起作用,并且miR-510和miR-509-5p可以被视为预测OSC结局的新型候选临床生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号